AiCure's adherence, behavior tracker for clinical trials, therapy collects $24.5M

AiCure, a nearly decade-old startup using artificial intelligence to measure medication adherence and other behavior during clinical trials or normal care, has brought in $24.5 million in Series C funding. Palisades Growth Capital led the raise, which also featured new backers Singtel Innov8, Asahi Kasei Corporation, Accelmed Growth Partners, and SpringRock Ventures. The round also included all of the company's existing institutional investors: Baird Capital, New Leaf Venture Partners, the Pritzker Group, Biomatics Capital, Tribeca Venture Partners, and Silicon Valley Bank. AiCure's interactive medical assistant, or IMA, collects visual and audio data from patients to quantify their engagement with a treatment program, allowing the tool to identify patients who are at higher risk of dropout or non-adherence. While care providers can use these capabilities to better target their therapies and cut off preventable medical costs, drug developers can also use these trends to hone in on underperforming trial sites identify enrollees who are deliberately not participating.